Annexon (ANNX) Expected to Post Quarterly Earnings on Thursday

Annexon (NASDAQ:ANNX) will likely be posting its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.23) per share and revenue of $6.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Annexon Trading Down 0.4%

ANNX stock opened at $5.39 on Tuesday. The company has a market cap of $883.10 million, a PE ratio of -4.42 and a beta of 1.18. The stock has a 50-day moving average price of $5.35 and a two-hundred day moving average price of $5.55. Annexon has a 12-month low of $2.03 and a 12-month high of $7.18.

Insider Transactions at Annexon

In other news, Director Muneer A. Satter acquired 613,497 shares of the stock in a transaction on Thursday, May 28th. The stock was bought at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the transaction, the director directly owned 10,342,134 shares of the company’s stock, valued at $55,950,944.94. The trade was a 6.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Annexon

A number of large investors have recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. acquired a new position in Annexon in the 4th quarter worth $50,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Annexon during the third quarter valued at about $31,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Annexon during the fourth quarter valued at about $52,000. Engineers Gate Manager LP purchased a new stake in shares of Annexon during the second quarter worth about $32,000. Finally, Cerity Partners LLC purchased a new stake in shares of Annexon during the fourth quarter worth about $74,000.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ANNX shares. Needham & Company LLC lifted their price objective on Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Citigroup started coverage on shares of Annexon in a research report on Tuesday, July 21st. They set a “market underperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Annexon in a report on Monday, July 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Monday, July 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Annexon in a research note on Tuesday, May 12th. They set a “neutral” rating and a $7.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Annexon currently has a consensus rating of “Hold” and a consensus price target of $15.33.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.